NextCure (NXTC) Return on Capital Employed (2019 - 2026)

NextCure's Return on Capital Employed history runs 8 years deep, the most recent figure standing at 150.85% for Q1 2026.

• In Q1 2026, Return on Capital Employed fell 7311.0% year-over-year to 150.85%; the TTM figure through Mar 2026 stood at 150.85% (down 7311.0% YoY), while the FY2025 annual figure was 104.84%, down 4187.0% from the prior year.
• Return on Capital Employed for Q1 2026 stood at 150.85%, up from 167.82% in the prior quarter.
• The five-year high for Return on Capital Employed was 32.86% in Q1 2022, with the low at 184.7% in Q3 2025.
• The 5-year median for Return on Capital Employed is 61.48% (2024), against an average of 78.89%.
• The sharpest annual moves came in 2023 and 2025: Return on Capital Employed plunged 969 bps in 2023, then plunged 11284 bps in 2025.
• NextCure's Return on Capital Employed stood at 42.67% in 2022, then declined by 25 bps to 53.21% in 2023, then tumbled by 48 bps to 78.59% in 2024, then slumped by 114 bps to 167.82% in 2025, then climbed by 10 bps to 150.85% in 2026.
• Business Quant data shows NXTC's Return on Capital Employed at 150.85% in Q1 2026, 167.82% in Q4 2025, and 184.7% in Q3 2025.